Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accumulated Depreciation (2018 - 2025)

Fortress Biotech has reported Accumulated Depreciation over the past 9 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $3.0 million for Q4 2025, down 70.12% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (down 70.12% YoY), and the annual figure for FY2025 was $3.0 million, down 70.12%.
  • Accumulated Depreciation for Q4 2025 was $3.0 million at Fortress Biotech, up from $2.9 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for FBIO hit a ceiling of $13.3 million in Q1 2023 and a floor of $2.7 million in Q1 2025.
  • Median Accumulated Depreciation over the past 5 years was $9.1 million (2023), compared with a mean of $8.5 million.
  • Biggest five-year swings in Accumulated Depreciation: surged 47.0% in 2021 and later plummeted 75.96% in 2025.
  • Fortress Biotech's Accumulated Depreciation stood at $9.4 million in 2021, then skyrocketed by 32.49% to $12.4 million in 2022, then fell by 28.56% to $8.9 million in 2023, then grew by 11.7% to $9.9 million in 2024, then plummeted by 70.12% to $3.0 million in 2025.
  • The last three reported values for Accumulated Depreciation were $3.0 million (Q4 2025), $2.9 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.